By Adriano Marchese
Enanta Pharmaceuticals said it saw positive results from its recent study evaluating a treatment for respiratory syncytial virus in newborns, also known as RSV.
The clinical-stage biotechnology company said Monday that topline results from the phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with RSV were positive.
RSV usually presents itself mildly, with people developing cold-like symptoms, but it is the leading cause of infant hospitalization in the U.S., according to the Centers for Disease Control and Prevention.
"Zelicapavir demonstrated an antiviral effect on both primary endpoints, as well as secondary virology endpoints," Chief Medical Officer Scott Rottinghaus said.
Enanta said it also saw a favorable safety profile for the drug over the initial five-day dosing period and through 23 days of follow-up.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
December 09, 2024 07:12 ET (12:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.